Published: Apr. 13, 2007
Updated: Apr. 13, 2007
National leaders in furthering the understanding and treatment of lung cancer
By Kathleen Yount
One of the benefits of seeking cancer care from an academic medical center is access to clinical trials testing the newest ideas in treatment. That’s particularly true at Duke, where physician-scientists are national leaders in furthering the understanding and treatment of lung cancer.
Duke medical oncologists are an important part of every patient care team. Oncologists who focus on lung cancer know they are battling a formidable foe. They also know that the best battle strategies come from a clear understanding of your enemy.
That’s why, in addition to providing patient care, many Duke oncologists also conduct groundbreaking research. Their aim is to not only help provide the best existing cancer care, but also help make those treatment options even better.
Oncologist Michael J. Kelley, MD, uses genetic studies to better understand rare pulmonary cancers. He also pursues the development of drug strategies to treat lung cancer based on genetic alterations in the tumor cells.
Neal Ready, MD, PhD, specializes in lung and head-and-neck cancers; he is studying new strategies to personalize chemotherapy treatment based on tumor gene expression. He also researches molecularly targeted therapeutic agents that could be applied to current standard cancer therapies.
Gordana Vlahovic, MD, investigates how molecular manipulation of a tumor’s physiology and biology may improve the effectiveness of cancer drugs. She is also evaluating new noninvasive imaging strategies that help identify each patient’s unique risk for cancer, identify tumors at an early stage, and assess a particular tumor’s potential responsiveness to certain therapies.
Research in lung cancer is conducted by many medical specialists on the Duke lung cancer care team. Highlights of other active lung cancer research include: